All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

atosiban 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
oxytocin antagonists	3008	90779-69-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: atosiban acetate atosiban Antocin II antocin tractocil tractocile	Atosiban is a synthetic peptide which is a competitive antagonist of human oxytocin at receptor level. In human pre-term labour, atosiban at the recommended dosage antagonises uterine contractions and induces uterine quiescence. Molecular weight: 994.19 Formula: C43H67N11O12S2 CLOGP: -0.02 LIPINSKI: 3 HAC: 23 HDO: 11 TPSA: 365.67 ALOGS: -4.28 ROTB: 18

Drug dosage:

Dose	Unit	Route
165	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 20, 2000	EMA	Ferring Pharmaceuticals A/S

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Premature delivery	757.29	252.17	155	829	30126	63457912
Normal labour	632.23	252.17	77	907	440	63487598
Delivery	547.13	252.17	76	908	1327	63486711
Maternal exposure during pregnancy	525.27	252.17	173	811	219889	63268149
Product use in unapproved indication	318.88	252.17	114	870	178966	63309072

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Premature delivery	159.77	127.24	31	209	23436	79720712
Maternal exposure during pregnancy	137.55	127.24	38	202	136500	79607648

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G02CX01	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Other gynecologicals
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D012102	Reproductive Control Agents
MeSH PA	D015149	Tocolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Prevention of Premature Labor	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.81	acidic
pKa2	12.85	acidic
pKa3	13.13	acidic
pKa4	13.53	acidic
pKa5	13.54	acidic
pKa6	13.87	acidic
pKa7	9.93	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Oxytocin receptor	GPCR	P30559	OXYR_HUMAN	ANTAGONIST	Ki	7.96		CHEMBL	DRUG LABEL
Vasopressin V1a receptor	GPCR	P37288	V1AR_HUMAN		Ki	9.82		CHEMBL
Vasopressin V1b receptor	GPCR	P47901	V1BR_HUMAN		Ki	7.36		CHEMBL
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN		Ki	6.48		CHEMBL
Oxytocin receptor	GPCR		OXYR_RAT		Ki	7.40		CHEMBL

External reference:

ID	Source
D03008	KEGG_DRUG
914453-95-5	SECONDARY_CAS_RN
C0164398	UMLSCUI
CHEBI:135899	CHEBI
CHEMBL382301	ChEMBL_ID
DB09059	DRUGBANK_ID
C047046	MESH_SUPPLEMENTAL_RECORD_UI
2213	IUPHAR_LIGAND_ID
6392	INN_ID
081D12SI0Z	UNII
5311010	PUBCHEM_CID
59639	RXNORM
008327	NDDF
008328	NDDF
326166008	SNOMEDCT_US
391792002	SNOMEDCT_US
427147004	SNOMEDCT_US

Pharmaceutical products:

None